Search for: "WATSON PHARMACEUTICALS "
Results 81 - 100
of 360
Sort by Relevance
|
Sort by Date
25 Jun 2013, 9:51 am
Watson Pharmaceuticals, Inc. [5] Citing FTC v. [read post]
24 Jun 2013, 10:08 am
Watson Pharmaceuticals, Inc. [5] Citing FTC v. [read post]
24 Jun 2013, 6:08 am
Watson Pharmaceuticals, Inc. [5] Citing FTC v. [read post]
18 Jun 2013, 10:24 am
Hatch-Waxman at the Supreme Court: Supporting Cert. in CiproOne of the most debated issues in patent and antitrust law today involves pharmaceutical patent settlements. [read post]
16 Jun 2013, 9:32 pm
Watson Laboratories Inc. et al. 1:13-cv-01015; filed June 6, 2013 in the District Court of Delaware • Plaintiff: Fresenius Kabi USA, LLC • Defendants: Watson Laboratories Inc.; Actavis Inc. [read post]
10 Jun 2013, 9:30 pm
Watson Pharmaceuticals, Inc, a case raising the question of the legality of these agreements. [read post]
2 May 2013, 2:22 am
TTAB Affirms 2(e)(4) Surname Refusal of "MERIWETHER" for Cabinetry Applicant Fails to Prove Historical Significance of "DAIMLER" for Vehicles, TTAB Affirms 2(e)(4) Surname Refusal TTAB Administers 2(e)(4) Kiss of Death to "SIMMONS COMICS GROUP" for Comic Books Despite Claim that "MERROW" Means "Mermaid," TTAB Affirms 2(e)(4) Surname RefusalTTAB Affirms Surname Refusal of "HARRINGTON OAK" for FlooringTTAB Reverses Surname Refusal of "CURLIN" for Medical Devices TTAB Affirms… [read post]
25 Apr 2013, 12:15 pm
Watson Pharmaceuticals, Inc., the Federal Circuit reversed the district court and held that Bayer’s patent covering its Yaz® birth control pill product is invalid as obvious. [read post]
24 Apr 2013, 9:46 pm
Watson Pharmaceuticals, Inc. [read post]
22 Apr 2013, 5:34 am
Watson Pharmaceuticals, 2013 WL 1405226 (D.N.J.) [read post]
11 Apr 2013, 4:57 am
FTC Sues Regarding AndroGel Patent SettlementThe Federal Trade Commission has filed a complaint in federal district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. to delay generic competition to Solvay’s branded testosterone-replacement drug AndroGel, a prescription pharmaceutical with annual sales of more than $400 million. [read post]
1 Apr 2013, 9:59 pm
Watson Pharmaceuticals, Inc. in the 11th Circuit opinion below) last Monday, with Deputy Solicitor General Malcolm Stewart arguing for the government and Jeffrey Weinberger arguing for Respondents. [read post]
1 Apr 2013, 8:29 am
” Upon receiving this reissue patent, Pfizer immediately filed a lawsuit against Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Watson Laboratories, Inc.; Lupin Pharmaceuticals, USA, Inc.; Apotex Corp.; and Apotex, Inc. in the United States District Court for the Eastern District of Virginia for infringement of the reissue patent. [read post]
25 Mar 2013, 9:59 pm
Watson Pharmaceuticals. [read post]
24 Mar 2013, 9:56 pm
Watson), in which the Court will decide when a brand-name pharmaceutical company may offer a "reverse payment" settlement to a generic company in exchange for the generic dropping a patent challenge and staying out of the market. [read post]
13 Mar 2013, 1:55 pm
Watson Pharmaceuticals, Inc., a case concerning reverse payment settlements of patent litigation. [read post]
13 Mar 2013, 4:45 am
Companies Agree to Sell Rights to 18 Drugs to Satisfy FTCThe Federal Trade Commission will require Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.... [read post]
12 Mar 2013, 6:40 am
Watson Pharmaceuticals, Inc., a case concerning reverse payment settlements of patent litigation. [read post]
10 Mar 2013, 9:59 pm
Searle LLC; Pfizer Asia Pacific PTE, LTD.; • Defendants: Lupin Pharmaceuticals, Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Watson Laboratories, Inc.; Apotex Inc.; Apotex Corp. [read post]
25 Feb 2013, 11:00 pm
Watson Pharmaceuticals, Inc., the Federal Circuit reversed the district court’s finding that two Orange Book-listed patents for Cephalon’s FENTORA® product were invalid, but affirmed the district court’s finding that Watson’s ANDA product would not... [read post]
